期刊
JOR SPINE
卷 5, 期 1, 页码 -出版社
WILEY
DOI: 10.1002/jsp2.1186
关键词
intervertebral disc degeneration; intradiscal injection; low back pain
类别
资金
- foundation of Shenzhen Committee for Science and Technology Innovation [JCYJ20190809142211354, GJHZ20180929160004704]
- Fundamental Research Funds for the Central Universities [19ykzd05]
- Sanming Project of Medicine in Shenzhen [SZSM201911002]
- Beijing Municipal Health Commission [BMHC2021-6, BMHC-2019-9, BMHC-2018-4, PXM2020]
- National Natural Science Foundation of China [81772400, 31900583, 32071351]
- Natural Science Foundation of Guangzhou City [201704030082, 201807010031, 201604046028]
Low back pain is a common clinical issue caused by intervertebral disc degeneration. Current treatments are limited due to their inability to address the underlying degeneration. Intradiscal injection therapies have shown benefits in symptomatic relief and disc repair, but there are limitations to consider.
Low back pain (LBP) is a common clinical problem and a major cause of physical disability, imposing a prominent socioeconomic burden. Intervertebral disc degeneration (IDD) has been considered the main cause of LBP. The current treatments have limited efficacy because they cannot address the underlying degeneration. With an increased understanding of the complex pathological mechanism of IDD, various medications and biological reagents have been used for intradiscal injection for the treatment of LBP. There is increasing clinical evidence showing the benefits of these therapies on symptomatic relief and their potential for disc repair and regeneration by targeting the disrupted pathways underlying the cause of the disease. A brief overview of the potential and limitations for these therapies are provided in this review, based on the recent and available data from clinical trials and systematic reviews. Finally, future perspectives are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据